Loading…
Employees: 535
Size Hainan Shuangcheng Pharmaceuticals (002693.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $476M, the 3970th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥7.78 on 6 Nov 2026.
Performance Over six months the shares fell 9.6%, against -20.6% for the median peer and -16.4% for the China market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue grew 40.4% over the last twelve months (peer median -6.3%); the operating margin is 13.4% (peer median 3.3%).
Valuation It trades at 11.1× enterprise value to sales against a peer median of 3.3× (5th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 45% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +44 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 6.0 points below its cost of capital (16.4% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥300M | CN¥276M | CN¥168M | CN¥234M | CN¥272M |
| Revenue growth | — | +64% | -28% | -14% | — |
| Gross profit | CN¥178M | CN¥121M | CN¥54.6M | CN¥149M | CN¥143M |
| EBITDA | n/a | CN¥72.5M | -CN¥16.3M | CN¥17.1M | CN¥14.3M |
| Net income | CN¥44.0M | CN¥19.0M | -CN¥78.3M | -CN¥50.7M | CN¥9.01M |
| Free cash flow | CN¥27.8M | CN¥18.2M | -CN¥65.0M | -CN¥34.8M | -CN¥3.08M |
| Capital expenditure | CN¥47.6M | CN¥43.3M | CN¥24.9M | CN¥49.2M | CN¥33.0M |
| Total debt | CN¥197M | CN¥214M | CN¥213M | CN¥151M | CN¥213M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002693.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.5% | -11.3% | 8th lowest of 20 |
| 6-month return | -9.6% | -20.6% | 7th highest of 20 |
| Distance from 52-week high | -37.4% | -40.7% | 8th highest of 20 |
| Revenue growth (TTM) | +40.4% | -6.3% | 2nd highest of 21 |
| Operating margin | 13.4% | 3.3% | 3rd highest of 21 |
| EV / Sales | 11.1× | 3.3× | 5th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 44.5% | 5.7% | 2nd most demanding of 12 |
| Growth delivered (Del g) | +1.0% | +0.7% | 6th highest of 12 |
| Hurdle (Req g minus delivered) | +43.5 pp | +3.8 pp | 2nd most demanding of 12 |
| ROIC minus cost of capital | -6.0 pp | -2.1 pp | 8th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $476M | -10% | +40% | 13% | 11.1× | 44.5% | +1.0% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $476M | +7% | -17% | -28% | 11.5× | n/a | n/a |
| Pulike Biological Engineering 603566.SS | China | $475M | -22% | -9% | 5% | 2.5× | 5.7% | +3.3% |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $477M | +62% | +10,947% | -194% | 132.2× | n/a | n/a |
| CytomX Therapeutics CTMX | United States | $477M | -45% | -87% | -477% | 8.3× | n/a | n/a |
| YungShin Global 3705.TW | Taiwan | $474M | +7% | -8% | 15% | 1.9× | -4.9% | +0.7% |
| Cachet Pharmaceutical 002462.SZ | China | $471M | -22% | -14% | 0% | 0.2× | -8.9% | -3.4% |
| Kexing Biopharm 688136.SS | China | $470M | -38% | -14% | -12% | 3.1× | n/a | n/a |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $470M | -39% | +35% | 4% | 1.2× | n/a | n/a |
| Alpha Teknova TKNO | United States | $482M | +104% | +12% | -35% | 11.3× | n/a | n/a |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $483M | +9% | -4% | 3% | 1.4× | 13.4% | +1.4% |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $484M | -23% | -14% | 12% | 0.5× | -18.6% | +6.3% |
| Daewoong 003090.KS | South Korea | $485M | -29% | +5% | 11% | 0.9× | n/a | n/a |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $467M | -13% | -5% | -29% | 4.5× | n/a | n/a |
| Evonile Pharma EVONILE.NS | India | $466M | n/a | -5% | 12% | 14.5× | 46.5% | -1.5% |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $466M | -20% | -21% | -68% | 9.0× | n/a | n/a |
| Teyi Pharmaceutical 002728.SZ | China | $465M | -9% | -7% | 7% | 3.5× | 26.6% | +8.0% |
| Shanghai Jiaoda Onlly 600530.SS | China | $464M | -22% | -2% | -2% | 10.4× | 33.5% | -0.9% |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $464M | -30% | +14% | 5% | 2.4× | 2.5% | -1.3% |
| PKU Healthcare 000788.SZ | China | $489M | -11% | -49% | 5% | 2.5× | -2.6% | -5.6% |
| Zhejiang Chengyi Pharmaceutical 603811.SS | China | $463M | -21% | +7% | 19% | 3.6× | 7.1% | +1.3% |